
Elite Pharmaceuticals, Inc. – OTC:ELTP
Elite Pharmaceuticals stock price today
Elite Pharmaceuticals stock price monthly change
Elite Pharmaceuticals stock price quarterly change
Elite Pharmaceuticals stock price yearly change
Elite Pharmaceuticals key metrics
Market Cap | 39.08M |
Enterprise value | 12.02M |
P/E | 2.95 |
EV/Sales | 0.36 |
EV/EBITDA | 1.43 |
Price/Sales | 0.90 |
Price/Book | 0.99 |
PEG ratio | 0.04 |
EPS | N/A |
Revenue | 43.23M |
EBITDA | 7.89M |
Income | 6.80M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 21.76% |
Oper. margin | 14.81% |
Gross margin | 48.69% |
EBIT margin | 14.81% |
EBITDA margin | 18.26% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeElite Pharmaceuticals stock price history
Elite Pharmaceuticals stock forecast
Elite Pharmaceuticals financial statements
Dec 2021 | 8.97M | 2.28M | 25.44% |
---|---|---|---|
Mar 2022 | 7.67M | 2.42M | 31.66% |
Mar 2023 | 8.64M | -1.22M | -14.22% |
Mar 2024 | 17.94M | 3.32M | 18.53% |
Sep 2022 | 50343250 | 23.15M | 45.99% |
---|---|---|---|
Dec 2022 | 52716134 | 22.54M | 42.76% |
Mar 2023 | 40896018 | 11.93M | 29.19% |
Mar 2024 | 83653536 | 26.07M | 31.17% |
Dec 2021 | 3.03M | -82.07K | -153.86K |
---|---|---|---|
Mar 2022 | 1.60M | -264.17K | -94.24K |
Mar 2023 | 2.96M | -536.21K | -12.50M |
Mar 2024 | 2.05M | -403.64K | -361.44K |
Elite Pharmaceuticals alternative data
Aug 2023 | 53 |
---|---|
Sep 2023 | 53 |
Oct 2023 | 53 |
Nov 2023 | 53 |
Dec 2023 | 53 |
Jan 2024 | 53 |
Feb 2024 | 53 |
Mar 2024 | 53 |
Apr 2024 | 53 |
May 2024 | 53 |
Jun 2024 | 53 |
Jul 2024 | 53 |
Elite Pharmaceuticals other data
Period | Buy | Sel |
---|---|---|
Apr 2015 | 0 | 85530 |
Nov 2015 | 0 | 150000 |
Jan 2016 | 0 | 115000 |
Feb 2016 | 0 | 995334 |
Mar 2016 | 0 | 570520 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Option | HAKIM NASRAT A director, 10 perc.. | Common Stock | 142,857,143 | N/A | N/A | ||
Option | HAKIM NASRAT A director, 10 perc.. | Series I Convertible Preferred Shares | 100 | N/A | N/A | ||
Sale | TREPPEL JERRY other: former Chairman | Common Stock | 258,090 | N/A | N/A | ||
Sale | TREPPEL JERRY other: former Chairman | Common Stock | 312,430 | N/A | N/A | ||
Sale | TREPPEL JERRY other: former Chairman | Common Stock | 100,456 | N/A | N/A | ||
Sale | TREPPEL JERRY other: former Chairman | Common Stock | 100,000 | N/A | N/A | ||
Sale | TREPPEL JERRY other: former Chairman | Common Stock | 50,000 | N/A | N/A | ||
Sale | TREPPEL JERRY other: former Chairman | Common Stock | 24,400 | N/A | N/A | ||
Sale | TREPPEL JERRY other: former Chairman | Common Stock | 349,660 | N/A | N/A | ||
Sale | TREPPEL JERRY other: former Chairman | Common Stock | 45,518 | N/A | N/A |
Quarter | Transcript |
---|---|
Q3 2024 15 Feb 2024 | Q3 2024 Earnings Call Transcript |
Q2 2024 17 Nov 2023 | Q2 2024 Earnings Call Transcript |
Q1 2024 15 Aug 2023 | Q1 2024 Earnings Call Transcript |
Q4 2023 30 Jun 2023 | Q4 2023 Earnings Call Transcript |
Insider | Compensation |
---|---|
Mr. Nasrat Hakim (1961) Chairman, Chief Executive Officer & Pres | $1,080,000 |
Mr. Douglas Plassche (1964) Executive Vice President of Operations | $348,540 |
-
What's the price of Elite Pharmaceuticals stock today?
One share of Elite Pharmaceuticals stock can currently be purchased for approximately $0.57.
-
When is Elite Pharmaceuticals's next earnings date?
Unfortunately, Elite Pharmaceuticals's (ELTP) next earnings date is currently unknown.
-
Does Elite Pharmaceuticals pay dividends?
No, Elite Pharmaceuticals does not pay dividends.
-
How much money does Elite Pharmaceuticals make?
Elite Pharmaceuticals has a market capitalization of 39.08M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 99.83% to 56.63M US dollars.
-
What is Elite Pharmaceuticals's stock symbol?
Elite Pharmaceuticals, Inc. is traded on the OTC under the ticker symbol "ELTP".
-
What is Elite Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers—Specialty & Generic industry.
-
How do i buy shares of Elite Pharmaceuticals?
Shares of Elite Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Elite Pharmaceuticals's key executives?
Elite Pharmaceuticals's management team includes the following people:
- Mr. Nasrat Hakim Chairman, Chief Executive Officer & Pres(age: 64, pay: $1,080,000)
- Mr. Douglas Plassche Executive Vice President of Operations(age: 61, pay: $348,540)
-
How many employees does Elite Pharmaceuticals have?
As Jul 2024, Elite Pharmaceuticals employs 53 workers.
-
When Elite Pharmaceuticals went public?
Elite Pharmaceuticals, Inc. is publicly traded company for more then 27 years since IPO on 23 Jul 1998.
-
What is Elite Pharmaceuticals's official website?
The official website for Elite Pharmaceuticals is elitepharma.com.
-
Where are Elite Pharmaceuticals's headquarters?
Elite Pharmaceuticals is headquartered at 165 Ludlow Avenue, Northvale, NJ.
-
How can i contact Elite Pharmaceuticals?
Elite Pharmaceuticals's mailing address is 165 Ludlow Avenue, Northvale, NJ and company can be reached via phone at +20 17502646.
Elite Pharmaceuticals company profile:

Elite Pharmaceuticals, Inc.
elitepharma.comOTC
43
Drug Manufacturers—Specialty & Generic
Healthcare
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and manufacture of oral, controlled-release products and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Oxycodone HCl immediate release 5mg, 10mg, 15mg, 20mg, and 30mg tablets for pains under Roxycodone brand; Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets for central nervous system diseases under the Adderall brand, as well as Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the brand Loxapine; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, and infection. Further, the company is developing a range of abuse deterrent opioid products. The company was incorporated in 1997 and is headquartered in Northvale, New Jersey.
Northvale, NJ 07647
CIK: 0001053369
ISIN: US28659T2006
: